Y-mAbs plunges after failing to win FDA AdCom backing for neuroblastoma therapy

Oct. 28, 2022 3:08 PM ETY-mAbs Therapeutics, Inc. (YMAB)By: Dulan Lokuwithana, SA News Editor

FDA Headquarters - White Oak Campus


Note: This article has been updated to reflect the decline in share price following the resumption of trading after Friday's market close.

  • Y-mAbs Therapeutics (NASDAQ:YMAB) is down 35% in after-hours trading on Friday after an expert

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.